Physician

Alexander M Vitievsky, M.D.

According to 2025 Medicare claims, Alexander Vitievsky, M.D. (NPI: 1447250303) practices nephrology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is EXCELCARE MEDICAL ASSOCIATES, PA (NPI: 1992736300; TIN: 203130405) and primary practice location at 07666-4245. Vitievsky is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Vitievsky's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 453 traditional Medicare patients, billed 1,817 HCPCS/CPT codes, and received $133,513 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,305 prescription claims across 202 beneficiaries totaling $230,875 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 108 claims. Open Payments data shows 31 records totaling $542. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $315,566 and ending at $230,875. In contrast, DME billing represents a smaller volume and declined steadily, from $2,273 to $1,106.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	544	4,466	$170,948
2016	535	3,457	$156,297
2017	515	3,902	$141,911
2018	509	5,372	$148,484
2019	513	3,554	$193,282
2020	452	2,152	$160,719
2021	413	2,033	$147,317
2022	419	2,188	$149,248
2023	426	2,896	$130,533
2024	453	1,817	$133,513

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	183	1,972	$315,566
2016	172	1,494	$282,500
2017	156	1,523	$351,151
2018	151	1,263	$304,350
2019	190	1,321	$251,035
2020	174	1,550	$244,998
2021	182	1,390	$304,738
2022	194	1,267	$214,438
2023	201	1,366	$336,397
2024	202	1,305	$230,875

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	112	$5,034
2016	N/R	86	$6,515
2017	11	104	$6,394
2018	N/R	84	$2,237
2019	N/R	85	$2,058
2020	N/R	121	$4,218
2021	N/R	154	$4,990
2022	N/R	121	$3,931
2023	N/R	103	$3,169
2024	N/R	108	$3,090

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	87	97	$150
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	53	53	$135
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	64	107	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	181	345	$75
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	149	363	$69

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	19	870	$58,822
Veltassa	Patiromer Calcium Sorbitex	31	1,410	$26,459
Januvia	Sitagliptin Phosphate	16	1,140	$20,656
Farxiga	Dapagliflozin Propanediol	18	960	$17,741
Eliquis	Apixaban	14	570	$10,847

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	19	$1,971
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$417
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	23	$326
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	18	$267
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	12	$96

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$542	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexander M. Vitievsky, M.D.?

Tedicare shows public-source Medicare data for Alexander M. Vitievsky, M.D. (NPI 1447250303), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander M. Vitievsky, M.D. have ACO affiliation data?

Alexander M. Vitievsky, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Alexander M. Vitievsky, M.D.?

Alexander M. Vitievsky, M.D. is linked to EXCELCARE MEDICAL ASSOCIATES, PA (billing NPI 1992736300) in the available physician profile data.

Does Alexander M. Vitievsky, M.D. have Open Payments data?

Alexander M. Vitievsky, M.D. has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.